Ansaldo Energia SpA - Strategic SWOT Analysis Review

Ansaldo Energia SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - The analyst’s summarization of the company’s business strategy.
SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Ansaldo Energia SpA (Ansaldo Energia) is a supplier of power plant equipment and related services. The company provides turnkey power plants, components such as gas and steam turbines, generators and microturbines. Its service offerings include engineering, procurement and construction of thermoelectric power plants, maintenance, repair, auto tuning, and spare parts services on existing plants, built by itself or other original equipment manufacturers (OEMs). The company also operates in the construction and dismantling of nuclear plants and the treatment of radioactive waste from existing plant. The company has operations in the Middle East, Asia, Europe, and North America. Ansaldo Energia is headquartered in Genova, Italy.

Ansaldo Energia SpA Key Recent Developments

May 21, 2026: ITER: Ansaldo Nucleare Completes Manufacturing and Integrated Testing of Remote Handling Infrastructure
Apr 21, 2026: Ansaldo Energia: Shareholders’ Meeting Renews the Company's Governing Bodies
Apr 17, 2026: Ansaldo Energia Conferma Il Proprio Coinvolgimento Nel Progetto Di Reindustrializzazione Del Sito Di Gioia Del Colle
Apr 01, 2026: Ansaldo Energia Returns to Profit; Board Approves Draft 2025 Financial Statements and 2026-2030 Industrial Plan

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Alpha Tau Medical Ltd Company Overview
Alpha Tau Medical Ltd Company Snapshot
Alpha Tau Medical Ltd Pipeline Products and Ongoing Clinical Trials Overview
Alpha Tau Medical Ltd - Pipeline Analysis Overview
Alpha Tau Medical Ltd - Key Facts
Alpha Tau Medical Ltd - Major Products and Services
Alpha Tau Medical Ltd Pipeline Products by Development Stage
Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
Alpha Tau Medical Ltd Pipeline Products Overview
Alpha DaRT Kit - Breast cancer
Alpha DaRT Kit - Breast cancer Product Overview
Alpha DaRT Kit - Breast cancer Clinical Trial
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia Product Overview
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia Clinical Trial
Alpha DaRT Kit - Liver Cancer
Alpha DaRT Kit - Liver Cancer Product Overview
Alpha DaRT Kit - Liver Cancer Clinical Trial
Alpha DaRT Kit - Neoadjuvant Rectal Cancer
Alpha DaRT Kit - Neoadjuvant Rectal Cancer Product Overview
Alpha DaRT Kit - Pancreatic Cancer
Alpha DaRT Kit - Pancreatic Cancer Product Overview
Alpha DaRT Kit - Pancreatic Cancer Clinical Trial
Alpha DaRT Kit - Recurrent Cervical Cancer
Alpha DaRT Kit - Recurrent Cervical Cancer Product Overview
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) Product Overview
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme Product Overview
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme Clinical Trial
Alpha DaRT Kit - Recurrent Gynecological Cancer
Alpha DaRT Kit - Recurrent Gynecological Cancer Product Overview
Alpha DaRT Kit - Recurrent Lung Cancer
Alpha DaRT Kit - Recurrent Lung Cancer Product Overview
Alpha DaRT Kit - Recurrent Lung Cancer Clinical Trial
Alpha DaRT Kit - Recurrent Prostate Cancer
Alpha DaRT Kit - Recurrent Prostate Cancer Product Overview
Alpha DaRT Kit - Recurrent Prostate Cancer Clinical Trial
Alpha DaRT kit - Recurrent Prostate Cancer
Alpha DaRT kit - Recurrent Prostate Cancer Product Overview
Alpha DaRT kit - Recurrent Prostate Cancer Clinical Trial
Alpha DaRT Kit - Recurrent Rectal Cancer
Alpha DaRT Kit - Recurrent Rectal Cancer Product Overview
Alpha DaRT Kit - Sarcoma
Alpha DaRT Kit - Sarcoma Product Overview
Alpha DaRT Kit - Skin Cancer
Alpha DaRT Kit - Skin Cancer Product Overview
Alpha DaRT Kit - Skin Cancer Clinical Trial
Alpha DaRT Kit - Vulvar Cancer
Alpha DaRT Kit - Vulvar Cancer Product Overview
Alpha DaRT Kit - Vulvar Cancer Clinical Trial
Alpha Tau Medical Ltd - Key Competitors
Alpha Tau Medical Ltd - Key Employees
Alpha Tau Medical Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Alpha Tau Medical Ltd, Recent Developments
Jul 21, 2026: Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival With Alpha DaRT in Combination With Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Spe
Jul 15, 2026: Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Jun 23, 2026: Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States With Alpha DaRT at Hadassah University Medical Center in Israel
Jun 12, 2026: FDA clears Alpha Tau to advance REGAIN trial enrolment
Jun 01, 2026: Alpha Tau Announces Strong Overall Survival Results From Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
May 11, 2026: Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
May 11, 2026: Alpha Tau concludes patient enrolment in ReSTART pivotal trial
May 05, 2026: Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT Head and Neck Cancer Combination with Pembrolizumab
May 04, 2026: Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026
Apr 27, 2026: Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Appendix
Methodology
About the Analyst
Contact the Publisher
Disclaimer

List of Tables

Alpha Tau Medical Ltd Pipeline Products and Ongoing Clinical Trials Overview
Alpha Tau Medical Ltd Pipeline Products by Equipment Type
Alpha Tau Medical Ltd Pipeline Products by Indication
Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
Alpha Tau Medical Ltd, Key Facts
Alpha Tau Medical Ltd, Major Products and Services
Alpha Tau Medical Ltd Number of Pipeline Products by Development Stage
Alpha Tau Medical Ltd Pipeline Products Summary by Development Stage
Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status
Alpha Tau Medical Ltd Ongoing Clinical Trials Summary
Alpha DaRT Kit - Breast cancer - Product Status
Alpha DaRT Kit - Breast cancer - Product Description
Alpha DaRT Kit - Breast cancer - A Pilot Feasibility and Safety Trial of Intratumoral Diffusing Alpha-emitter Radiation Therapy (DaRT) for the Treatment of Newly Diagnosed or Recurrent Breast Carcinoma in Frail or Elderly Patients
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - Product Status
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - Product Description
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha DaRT Kit - Cutaneous and Mucosal Neoplasia - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha DaRT Kit - Liver Cancer - Product Status
Alpha DaRT Kit - Liver Cancer - Product Description
Alpha DaRT Kit - Liver Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Liver Metastases
Alpha DaRT Kit - Neoadjuvant Rectal Cancer - Product Status
Alpha DaRT Kit - Neoadjuvant Rectal Cancer - Product Description
Alpha DaRT Kit - Pancreatic Cancer - Product Status
Alpha DaRT Kit - Pancreatic Cancer - Product Description
Alpha DaRT Kit - Pancreatic Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer
Alpha DaRT Kit - Pancreatic Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Locally Advanced Pancreatic Cancer
Alpha DaRT Kit - Pancreatic Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters on Advanced Pancreatic Cancer
Alpha DaRT Kit - Pancreatic Cancer - A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters with Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Alpha DaRT Kit - Pancreatic Cancer - A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Alpha DaRT Kit - Recurrent Cervical Cancer - Product Status
Alpha DaRT Kit - Recurrent Cervical Cancer - Product Description
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - Product Status
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - Product Description
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - A Investigator-Initiated Study to Evaluate the Efficacy of Alpha DaRT Treatment in Immunocompromised Subjects with Recurrent Cutaneous Squamous Cell Carcinoma
Alpha DaRT Kit - Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - A Safety and Efficacy Study of Intratumoral Diffusing Alpha Radiation Emitters in Recurrent Unresectable or Metastatic Head and Neck Squamous Cell Carcinoma
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - Product Status
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - Product Description
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - A Clinical Study to Assess the Effects of Alpha DaRT Kit for the Treatment of Brain Cancer
Alpha DaRT Kit - Recurrent Glioblastoma Multiforme - A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
Alpha DaRT Kit - Recurrent Gynecological Cancer - Product Status
Alpha DaRT Kit - Recurrent Gynecological Cancer - Product Description
Alpha DaRT Kit - Recurrent Lung Cancer - Product Status
Alpha DaRT Kit - Recurrent Lung Cancer - Product Description
Alpha DaRT Kit - Recurrent Lung Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Recurrent Lung Cancer
Alpha DaRT Kit - Recurrent Prostate Cancer - Product Status
Alpha DaRT Kit - Recurrent Prostate Cancer - Product Description
Alpha DaRT Kit - Recurrent Prostate Cancer - A Pilot Clinical study to Evaluate Alpha DaRT Technology for the Treatment of Patients with Locally Recurrent Prostate Cancer
Alpha DaRT kit - Recurrent Prostate Cancer - Product Status
Alpha DaRT kit - Recurrent Prostate Cancer - Product Description
Alpha DaRT kit - Recurrent Prostate Cancer - A Feasibility and Safety Study of Focal Interstitial Radiotherapy Using Diffusing Alpha Emitters Radiation Therapy (DaRT) Seeds in Men With Non-metastatic Locally Recurrent Prostate Cancer
Alpha DaRT kit - Recurrent Prostate Cancer - A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Locally Recurrent Prostate Cancer
Alpha DaRT Kit - Recurrent Rectal Cancer - Product Status
Alpha DaRT Kit - Recurrent Rectal Cancer - Product Description
Alpha DaRT Kit - Sarcoma - Product Status
Alpha DaRT Kit - Sarcoma - Product Description
Alpha DaRT Kit - Skin Cancer - Product Status
Alpha DaRT Kit - Skin Cancer - Product Description
Alpha DaRT Kit - Skin Cancer - A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma
Alpha DaRT Kit - Skin Cancer - A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous Tumors
Alpha DaRT Kit - Skin Cancer - A Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma
Alpha DaRT Kit - Vulvar Cancer - Product Status
Alpha DaRT Kit - Vulvar Cancer - Product Description
Alpha DaRT Kit - Vulvar Cancer - A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva
Alpha DaRT Kit - Vulvar Cancer - A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters (DaRT) for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva
Alpha Tau Medical Ltd, Key Employees
Alpha Tau Medical Ltd, Other Locations
Alpha Tau Medical Ltd, Subsidiaries
Glossary

List of Figures

Alpha Tau Medical Ltd Pipeline Products by Equipment Type
Alpha Tau Medical Ltd Pipeline Products by Development Stage
Alpha Tau Medical Ltd Ongoing Clinical Trials by Trial Status

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€225EUR$250USD£192GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€337EUR$375USD£289GBP